Category: CLL in Focus
The Sequencing of Covalent and Noncovalent BTK Inhibitors in CLL
H&O What are the most important differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors? JW The covalent BTK inhibitors that have US Food and […]
Fixed-Duration vs Continuous Treatment for Chronic Lymphocytic Leukemia in the CLL17 Trial
H&O What was the impetus for the CLL17 trial? OA Over the past 5 to 10 years, we have seen the evolution of 2 treatment paradigms […]